Compare Cassava Sciences Inc (FLNA) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs JD.Com Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while JD.Com Inc trades at $29.78 (market cap $40.31B). The key difference: JD.Com Inc is far larger — about 758.6× Cassava Sciences Inc's market cap, and JD.Com Inc pays a 3.42% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | JD | |
|---|---|---|
Market Cap | $53.14M | $40.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $36.17 |
52-Week Low | $1.09 | $25.19 |
Enterprise Value | -$33.43M | $26.46B |
Dividend Yield | — | 3.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
JD.com (JD) trades at $29.77, up 3.22% today, with strong analyst consensus pointing to a $39.50 price target. The stock shows bullish technical signals and has beaten earnings estimates in recent quarters, though net income margin compressed to 1.05% in 2025. Recent news highlights institutional interest and Zacks Strong Buy rating as of July 14, 2026.
The outlook remains positive given valuation discounts (P/S 0.22) and earnings beats, but risks include ongoing legal investigations and Chinese market volatility. Upside potential is supported by cash flow strength and buyback programs, yet investors should weigh margin pressures against growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
